Turnover for the nine months ended 30 September 2026
Filed with HKEX · Stock code 2877 · · 1 page · English
Summary by 6ix AI
The turnover for the Group was reported at a substantial amount, with declines noted across various product categories including injection products and soft capsules. The announcement advises shareholders and investors to exercise caution in trading the company's shares due to these results.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
China Shineway Pharmaceutical Group Limited on 6ix
Earlier from China Shineway Pharmaceutical
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- List of Directors and their Role and Function
- Appointment of executive director
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Retirement of executive director and change of composition of board committees
Follow China Shineway Pharmaceutical into a list and get an email when it puts out news.
Follow China Shineway Pharmaceutical